---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024476"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:05:03.883742+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics Q3 2022 operating loss $22.3M; cash $209.6M funds through 2025

## Summary
- Cash $209.6M as of Sep 30, 2022; expected to fund operations and milestones through 2025.
- BDC-1001 dose-escalation trial on track to complete enrollment by year-end; topline data and RP2D expected Q1 2023.
- BDC-3042 IND-enabling progressing; on track for clinical entry in 2023.
- Collaboration revenue $2.1M (up from $0.8M YoY); R&D expense $19.0M, G&A $5.5M.
- Loss from operations $22.3M vs $23.5M in Q3 2021.

## SEC filing metadata
- accession: 0000950170-22-024476
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017022024476/0000950170-22-024476-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017022024476/bolt-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024476
- JSON: https://secwatch.observer/filing/0000950170-22-024476.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024476.txt

## Key facts
- Earnings Releases
  Bolt Biotherapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $2.1 million.
  - Period: third quarter ended September 30, 2022
  - Revenue: $2.1 million
  - Result: reported results
  source text: 16th, 2022, with a corporate presentation at 1:15 p.m. ET in New York, New York. Third Quarter 2022 Financial Results • Collaboration Revenue – Collaboration revenue was $2.1 million for the third quarter ended September 30, 2022, compared to $0.8 million for the same quarter in 2021. This represents 50% growth over the second quarter of 2022 as Bolt
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000095017022024476/0000950170-22-024476-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.